Kairos Pharma, Ltd. (KAPA) Key Metrics
KAPA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.0M
- Enterprise value
- $2.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.44
KAPA key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKAPA valuation Price multiples at each fiscal year-end price.
KAPA returns How much profit the business earns on the capital it uses.
KAPA per-share figures Results divided by the shares outstanding at year-end.
KAPA financial health Debt, liquidity and how easily interest is covered.
KAPA valuation history
KAPA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KAPA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KAPA price vs earnings per share
KAPA key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $13.1M | $17.3M | — | — | — | — |
| Enterprise value | $8.6M | $16.0M | — | — | — | — |
| Price / book | 2.1 | 3.6 | — | — | — | — |
| Earnings yield | −41.6% | −15.1% | — | — | — | — |
| Free cash flow yield | −26.3% | −22.9% | — | — | — | — |
| Share price at fiscal year-end | $4.97 | $10.64 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.07 | −$1.60 | −$1.22 | −$0.72 | −$1.17 | −$0.66 |
| Operating cash flow per share | −$1.31 | −$2.44 | $0.05 | −$0.24 | −$0.22 | −$0.02 |
| Free cash flow per share | −$1.31 | −$2.44 | $0.05 | −$0.24 | −$0.22 | −$0.02 |
| Cash per share | $1.71 | $0.78 | $0.06 | $0.30 | $0.04 | $0.01 |
| Book value per share | $2.41 | $2.94 | −$1.40 | −$0.81 | −$0.64 | −$0.21 |
| Tangible book value per share | $2.39 | $2.81 | −$1.66 | −$1.18 | −$1.02 | −$0.21 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | $0.43 | $0.40 | $0.21 | $0.03 |
| Shares outstanding | 2.6M | 1.6M | 1.5M | 1.5M | 1.8M | 1.6M |
| Change in shares outstanding | +62.3% | +9.4% | +1.4% | −20.3% | +14.5% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −98.0% | −193.0% | — | — | — | — |
| Return on invested capital (ROIC) | −164.4% | −187.8% | — | — | — | — |
| Return on assets (ROA) | −85.4% | −72.5% | −181.1% | −116.0% | −543.5% | — |
| Return on tangible assets | −84.1% | −43.4% | −310.8% | −212.6% | — | — |
| Financial health | ||||||
| Total debt | — | — | $638,000 | $586,000 | $380,000 | $50,000 |
| Cash & short-term investments | $4.5M | $1.3M | $93,000 | $437,000 | $73,000 | $14,308 |
| Net debt | −$4.5M | −$1.3M | $545,000 | $149,000 | $307,000 | $35,692 |
| Debt / assets | — | — | 0.66 | 0.57 | 0.49 | 3.49 |
| Current ratio | 27.07 | 4.20 | 0.04 | 0.27 | 0.04 | 0.04 |
| Quick ratio | 27.07 | 4.20 | 0.04 | 0.27 | 0.04 | 0.04 |
| Interest coverage | — | -2.7 | -17.5 | -1.2 | -9.6 | -193.3 |
| Working capital | $5.2M | $3.2M | −$2.3M | −$1.2M | −$1.9M | −$342,838 |
| Invested capital | $1.9M | $3.5M | −$1.5M | −$1.0M | −$860,000 | −$307,146 |
| Tangible asset value | $6.3M | $4.6M | −$2.5M | −$1.7M | −$1.9M | −$342,838 |
| Net current asset value | $5.2M | $2.7M | −$2.9M | −$1.8M | −$1.9M | −$342,838 |
| Graham net-net per share | $1.63 | −$0.10 | −$1.99 | −$1.22 | −$1.02 | −$0.21 |
| Capital allocation | ||||||
| Capex / operating cash flow | — | — | 0.0% | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Efficiency | ||||||
| Days payables outstanding | — | 3,870.1 | 4,596.7 | 3,623.8 | 3,454.7 | — |
| Payables turnover | — | 0.09 | 0.08 | 0.10 | 0.11 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $595,500 | $1.7M | $2.0M | $1.6M | $927,573 | $307,146 |
| Intangibles / total assets | 0.9% | 3.6% | 39.6% | 52.3% | 90.6% | 0.0% |
Computed from KAPA's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KAPA valuation and financial ratios
Kairos Pharma earned a return on equity of −98.0% and a return on invested capital of −164.4% in fiscal 2025. The share count rose 64.3% from 1.6M to 2.6M over 5 years.
See the KAPA income statement, the KAPA chart for price history, or the KAPA stock overview for the latest quote and news.
KAPA key metrics FAQ
What is Kairos Pharma's return on equity?
Kairos Pharma's return on equity (ROE) was −98.0% in fiscal 2025: net income of -$5.4 million on average shareholders' equity of $5.6 million.
What is Kairos Pharma's ROIC?
Kairos Pharma's return on invested capital was −164.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Kairos Pharma's free cash flow yield?
Kairos Pharma generated -$3.4 million of free cash flow in fiscal 2025, a free cash flow yield of −26.3% on its market value at year-end ($13.1 million).
What is Kairos Pharma's current ratio?
Kairos Pharma's current ratio was 27.07 at the end of fiscal 2025: current assets were 27.07 times current liabilities.